Biocon's Novel Diabetes Education Initiative for Medical Practitioners 'ABIDE' Awarded by RSSDI

29 Nov 2016 Evaluate

Biocon's social responsibility initiative ‘ABIDE’, a unique diabetes education initiative for medical practitioners, which has been making a significant impact across the country, has now been conferred with the 'Award of Recognition' for its benefits, coverage and impeccable quality of delivery by the prestigious Research Society for the Study of Diabetes in India (RSSDI).

ABIDE is a 'paradigm-shifting' initiative designed to empower primary care physicians who treat diabetes on a regular basis. The courses are delivered in a non-commercial setting and offer learning opportunities through 'experience sharing' during the intensive deliberations in small group engagements. The pragmatic and application-based approach of ABIDE has helped physicians improve their practice with enriched patient connect and enhanced clinical outcomes. Biocon plans to expand the ambit of the ABIDE program for the benefit of a wider group of healthcare providers.

Biocon is India's largest and fully-integrated, innovation-led biopharmaceutical company.

 

Biocon Share Price

392.80 4.55 (1.17%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×